Rigel Pharmaceuticals (RIGL) Current Assets (2010 - 2026)

Rigel Pharmaceuticals' Current Assets history runs 17 years deep, the most recent figure standing at $234.0 million for Q1 2026.

• In Q1 2026, Current Assets rose 59.68% year-over-year to $234.0 million; the TTM figure through Mar 2026 stood at $234.0 million (up 59.68% YoY), while the FY2025 annual figure was $240.2 million, up 77.77% from the prior year.
• Current Assets was $234.0 million for Q1 2026 at Rigel Pharmaceuticals, down from $240.2 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $240.2 million in Q4 2025 to a low of $92.5 million in Q1 2024.
• Historically, Current Assets has averaged $136.9 million across 5 years, with a median of $115.9 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Current Assets slumped 35.45% in 2022, then jumped 101.87% in 2025.
• A 5-year view of Current Assets shows it stood at $115.9 million in 2022, then retreated by 14.35% to $99.3 million in 2023, then soared by 36.1% to $135.1 million in 2024, then jumped by 77.77% to $240.2 million in 2025, then fell by 2.56% to $234.0 million in 2026.
• The last three Current Assets figures came in at $234.0 million (Q1 2026), $240.2 million (Q4 2025), and $214.9 million (Q3 2025), per Business Quant data.